IN2014MN02338A - - Google Patents

Info

Publication number
IN2014MN02338A
IN2014MN02338A IN2338MUN2014A IN2014MN02338A IN 2014MN02338 A IN2014MN02338 A IN 2014MN02338A IN 2338MUN2014 A IN2338MUN2014 A IN 2338MUN2014A IN 2014MN02338 A IN2014MN02338 A IN 2014MN02338A
Authority
IN
India
Prior art keywords
inhibitors
relates
present
tec
members
Prior art date
Application number
Other languages
English (en)
Inventor
Alain Laurent
Yannick Rose
James B Jaquith
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2779184A external-priority patent/CA2779184A1/en
Priority claimed from CA2813299A external-priority patent/CA2813299A1/en
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Publication of IN2014MN02338A publication Critical patent/IN2014MN02338A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
IN2338MUN2014 2012-05-31 2013-05-28 IN2014MN02338A (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2779184A CA2779184A1 (en) 2012-05-31 2012-05-31 Protein kinase inhibitors
CA2813299A CA2813299A1 (en) 2013-04-17 2013-04-17 Protein kinase inhibitors
PCT/CA2013/000513 WO2013177668A1 (en) 2012-05-31 2013-05-28 Protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN02338A true IN2014MN02338A (lt) 2015-08-14

Family

ID=49672221

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2338MUN2014 IN2014MN02338A (lt) 2012-05-31 2013-05-28

Country Status (11)

Country Link
US (1) US9796716B2 (lt)
EP (1) EP2855484A4 (lt)
JP (1) JP6175495B2 (lt)
KR (2) KR101972990B1 (lt)
CN (1) CN104379586B (lt)
BR (1) BR112014029718A2 (lt)
CA (1) CA2874211A1 (lt)
HK (1) HK1208460A1 (lt)
IN (1) IN2014MN02338A (lt)
RU (1) RU2678767C2 (lt)
WO (1) WO2013177668A1 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833867A1 (en) * 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
CA2834528A1 (en) * 2013-11-26 2015-05-26 Pharmascience Inc. Protein kinase inhibitors
BR112017000470B1 (pt) * 2014-07-07 2022-11-29 Jiangsu Hengrui Medicine Co., Ltd Compostos, composição farmacêutica e uso do composto ou da composição
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
EP3337805A4 (en) * 2015-05-27 2019-04-03 Pharmascience Inc. INHIBITORS OF THE ENZYME FAMILY KINASES TEC
JP6428951B2 (ja) * 2015-12-07 2018-11-28 Dic株式会社 重合性化合物の製造方法
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
CN109369654A (zh) * 2018-11-20 2019-02-22 山东大学 1，3-二取代-4-氨基吡唑并嘧啶类化合物及其制备方法和应用
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2023083373A1 (zh) * 2021-11-15 2023-05-19 微境生物医药科技(上海)有限公司 作为Src抑制剂的化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CZ2002936A3 (cs) * 1999-09-17 2002-10-16 Abbott Gmbh & Co. Kg Pyrazolopyrimidiny jako terapeutické prostředky
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
SK13752001A3 (sk) * 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
AUPR392301A0 (en) 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
CA2810339A1 (en) * 2001-08-10 2003-02-20 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
SI2530083T1 (sl) * 2006-09-22 2016-09-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
ES2562215T3 (es) * 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
ES2749504T3 (es) * 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
WO2014187319A1 (en) * 2013-05-21 2014-11-27 Jiangsu Medolution Ltd Substituted pyrazolopyrimidines as kinases inhibitors
CN103787839B (zh) 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 合成2,3,4,5,6-五氟苯酚的方法

Also Published As

Publication number Publication date
CN104379586A (zh) 2015-02-25
RU2678767C2 (ru) 2019-02-01
BR112014029718A2 (pt) 2017-06-27
KR101972990B1 (ko) 2019-04-26
CA2874211A1 (en) 2013-12-05
JP2015518009A (ja) 2015-06-25
US20150191473A1 (en) 2015-07-09
EP2855484A1 (en) 2015-04-08
KR20190043648A (ko) 2019-04-26
KR20150015527A (ko) 2015-02-10
RU2014145285A (ru) 2016-07-20
CN104379586B (zh) 2018-01-16
US9796716B2 (en) 2017-10-24
WO2013177668A1 (en) 2013-12-05
HK1208460A1 (en) 2016-03-04
EP2855484A4 (en) 2015-12-16
JP6175495B2 (ja) 2017-08-02

Similar Documents

Publication Publication Date Title
IN2014MN02338A (lt)
ZA201600648B (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
HK1206298A1 (en) Compounds useful as inhibitors of atr kinase and combination therapies thereof atr
HK1215577A1 (zh) 蛋白激酶抑制劑
HK1212336A1 (en) Azaquinazoline inhibitors of atypical protein kinase
MX355728B (es) Inhibidores de cinasas.
ZA201405140B (en) Disubstituted benzothienyl-pyrolotriazines and their use as fgfr kinase inhibitors
HK1202333A1 (en) Combination of kinase inhibitors and uses thereof
MX343929B (es) Inhibidores de proteina cinasa.
PL2880035T3 (pl) Nowe związki pirolopirymidynowe jako inhibitory kinaz białkowych
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
HK1209726A1 (en) Protein kinase inhibitors
HK1205506A1 (en) Protein kinase inhibitors
HK1210036A1 (en) Aminoisoquinoline derivatives as protein kinase inhibitors
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors
MX2014012837A (es) Intermediarios y procesos para preparar compuestos.
GB201206048D0 (en) Novel compounds and their use as kinase inhibitors